Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARVN vs RCKT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARVN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

ARVN Overall Winner 6-Pillar Tally: ARVN 4 – 1 RCKT (1 Tie) Matrix Metrics: ARVN 7 – 3 RCKT

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Rocket Pharmaceuticals, Inc. (RCKT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin), whereas RCKT carries 50.2/100 (HOLD) at $2.19 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. RCKT 50.2/100 HOLD) and 1.40β · 66% Vol risk profile, whereas RCKT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile RCKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARVN vs RCKT
ARVN NASDAQ Head-to-Head Winner
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57
RCKT NASDAQ
Rocket Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$2.19
-5.0% 1D
Market Cap $262.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.76β · 67% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 17.0 Fund 52.0 Flow 69.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $2.41 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (ARVN 4 – 1 RCKT)

Columns: Metric · ARVN · RCKT
1. Valuation Multiples ARVN
Forward P/E 17.9x N/M
Trailing P/E 17.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x N/M
2. Growth & Scale ARVN
Revenue Growth (YoY) -98.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $275M N/A
Market Cap $449.9M $262.4M
3. Profitability & Quality RCKT
Gross Margin 96.7% N/A
Operating Margin -10.1% 0.0%
Net Profit Margin -3.5% 0.0%
Return on Equity (ROE) -1.8% -4.8%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$160M -$170M
Cash Flow Margin -58.0% N/A
Net Cash / Leverage $81M Net Cash $200M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARVN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 108.7% (25th %ile) 83.9% (30th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARVN (7) vs RCKT (3)
Institutional Metric ARVN RCKT Criterion Row Edge
Market Capitalization
Scale
$449.9M $262.4M Larger Scale ARVN
Trailing P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-98.8% +0.0% Higher Growth RCKT
Operating Margin (TTM)
Profitability
-10.1% 0.0% Higher Margin RCKT
Net Profit Margin
Profitability
-3.5% 0.0% Higher Margin RCKT
Return on Equity (ROE)
Capital Efficiency
-1.8% -4.8% Higher ROE ARVN
52-Week Range Position
Momentum
5% ($6–$15) 1% ($2–$5) Stronger Trend ARVN
Beta / 30D Volatility
Risk Regime
1.40β · 66% Vol 1.76β · 67% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
52.9 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$275M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($81M Net Cash) -$170M ($200M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCKT +3.53 pp
ARVN: -3.3% · RCKT: +0.23%
3M Horizon ARVN +7.37 pp
ARVN: -27.21% · RCKT: -34.58%
6M Horizon ARVN +5.6 pp
ARVN: -23.23% · RCKT: -28.83%
1Y Horizon RCKT +2.33 pp
ARVN: -33.4% · RCKT: -31.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARVN vs RCKT. Trailing 12-month operating profitability (ARVN -10.1% vs RCKT 0.0%) and valuation multiples (ARVN 17.9x vs RCKT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ARVN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$275M
Gross Margin96.7%
Op. Margin-10.1%
ROE / Fwd P/E-1.8% · 17.9x
RCKT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-4.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCKT BREAKDOWN
92d in phase · OBV DISTRIBUTION
Current IV 83.9%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RCKT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCKT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $262.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARVN vs RCKT Key Questions & Quantitative Answers

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Rocket Pharmaceuticals, Inc. (RCKT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin), whereas RCKT carries 50.2/100 (HOLD) at $2.19 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. RCKT 50.2/100 HOLD) and 1.40β · 66% Vol risk profile, whereas RCKT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile RCKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with RCKT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ARVN generates $275M in USD-normalized revenue versus N/A for RCKT. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCKT.

ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas RCKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus RCKT (-4.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, RCKT carries 83.9% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.76β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.